STOCK TITAN

Caris Life Sciences Completes Interim Readout of Achieve 1 Study

(Moderate)
(Positive)
Tags

Caris Life Sciences (NASDAQ: CAI) announced an interim readout of Achieve 1 for its Caris Detect multi-cancer early detection test on Feb 26, 2026. The interim dataset (2,122 samples) showed stage I sensitivity 56.8%, stage II 70.1%, and overall Stage I–II sensitivity 61.3%.

The study reported specificity 99.1% in an asymptomatic screening subgroup (n=121) and 95.3% in the undiagnosed population (n=1,505). A blinded validation (~865 samples) is in process with results expected later in Q1 2026.

Loading...
Loading translation...

Positive

  • Stage I sensitivity 56.8% in 266 cases
  • Stage I–II sensitivity 61.3% across cancers
  • Specificity 99.1% in asymptomatic screening (n=121)
  • Large molecular database >1M cases and >50B markers

Negative

  • Undiagnosed-population specificity lower at 95.3% (n=1,505)
  • Stage I sensitivity leaves nearly half of early cancers undetected

News Market Reaction – CAI

+4.68%
8 alerts
+4.68% News Effect
+16.0% Peak in 10 min
+$243M Valuation Impact
$5.43B Market Cap
0.0x Rel. Volume

On the day this news was published, CAI gained 4.68%, reflecting a moderate positive market reaction. Argus tracked a peak move of +16.0% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $243M to the company's valuation, bringing the market cap to $5.43B at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details interim Achieve 1 results for Caris Detect, showing early‑stage sensitivit...
Analysis

This announcement details interim Achieve 1 results for Caris Detect, showing early‑stage sensitivity of 61.3% and specificity up to 99.1% in key cohorts across 2,122 subjects. It underscores Caris’ strategy of leveraging Whole Genome Sequencing and AI atop more than 1,000,000 profiled cases and 50 billion molecular markers to enter multi‑cancer early detection. Investors may watch for the blinded validation results expected later in Q1 2026 and subsequent commercialization progress.

Key Figures

Stage I sensitivity: 56.8% (n=266) Stage IV sensitivity: 99.1% (n=109) Specificity (asymptomatic): 99.1% (n=121) +5 more
8 metrics
Stage I sensitivity 56.8% (n=266) Achieve 1 interim readout for Caris Detect
Stage IV sensitivity 99.1% (n=109) Achieve 1 interim readout for Caris Detect
Specificity (asymptomatic) 99.1% (n=121) Asymptomatic Screening Population
Specificity (undiagnosed) 95.3% (n=1,505) Undiagnosed Population
Total sample size 2,122 subjects Achieve 1 study (1,505 undiagnosed; 617 cancers)
Stage I–II sensitivity 61.3% Early-stage cancers across multiple types
Cases profiled Over 1,000,000 Caris molecular profiling database underpinning AI models
Molecular markers Over 50 billion Molecular markers in Caris’ profiling dataset

Historical Context

5 past events · Latest: Feb 24 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Feb 24 AI signature launch Positive +3.2% Unveiled AI breast cancer signature added to MI Cancer Seek report.
Feb 23 Conference participation Neutral -9.7% Announced participation in TD Cowen health care conference.
Feb 09 Earnings call scheduled Neutral +1.4% Set date and webcast details for Q4 and full-year 2025 results.
Jan 28 Real-world data study Positive +1.9% Published multiomic analysis of 2,799 T‑DXd–treated metastatic breast cancer patients.
Jan 12 Prelim 2025 results Positive -10.2% Reported strong preliminary Q4 and 2025 revenue growth and cash balance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has mostly been positive scientific/commercial updates, with generally positive price reactions, but the strong preliminary 2025 results saw a notable negative divergence.

Recent Company History

Over recent months, Caris reported strong preliminary 2025 results with Q4 revenue around $281 million and full‑year revenue near $800 million, driven by molecular profiling growth. Scientific updates included a large real‑world study in 2,799 metastatic breast cancer patients and an AI‑driven breast cancer signature using over 2,000 features, both supporting its precision oncology platform. Conference participation and an earnings date announcement rounded out corporate activity. Today’s Achieve 1 interim readout extends this trajectory into multi‑cancer early detection, leveraging the same genomics and AI capabilities.

Key Terms

whole genome sequencing, methylation-based, multi-cancer early detection (mced), molecular profiling, +3 more
7 terms
whole genome sequencing medical
"through Whole Genome Sequencing, advanced AI and molecular insights."
Whole genome sequencing is a laboratory method that reads an individual’s complete DNA instruction book, capturing all genetic letters rather than just selected parts. For investors, it matters because it can reveal new ways to diagnose, prevent or treat disease and to develop tests or drugs — like upgrading from a map of a few streets to a full city blueprint — which can create commercial opportunities, influence regulatory pathways and change healthcare costs and demand.
methylation-based medical
"superiority of Whole Genome Sequencing compared to methylation-based approaches"
Methylation-based describes tests, products or methods that detect patterns of small chemical tags attached to DNA; these tags act like molecular fingerprints that change with disease, age or cell type. For investors, such approaches matter because they can enable earlier, more specific diagnosis or monitoring than older tests, potentially driving clinical adoption, recurring revenue and regulatory scrutiny—so commercial success hinges on accuracy, scalability and approval.
multi-cancer early detection (mced) medical
"Caris Detect™, its multi-cancer early detection (MCED) test."
A multi-cancer early detection (MCED) test is a single medical test, often a blood test, designed to screen for signs of many different cancers at once rather than targeting one type. Investors care because successful MCEDs could reshape healthcare by catching disease earlier, expanding screening markets, cutting long-term treatment costs, and creating large commercial and regulatory opportunities similar to how a single smartphone can replace many separate devices.
molecular profiling medical
"Caris' industry-leading molecular profiling data, which has surpassed one million cases"
Molecular profiling is a laboratory analysis that reads a patient’s disease at the level of genes, proteins or other molecules to reveal its specific characteristics—think of it as reading the instruction manual for a tumor or condition. For investors, it matters because the results guide which targeted treatments, diagnostics or tests will be used, shaping clinical demand, regulatory approval paths and potential revenue for companies developing precision medicines and companion tests.
epigenomics medical
"driver mutations, changes in epigenomics, changes in transcriptomics"
Epigenomics is the study of chemical marks and patterns across the genome that turn genes on or off without changing the DNA sequence, like software switches controlling the same hardware. For investors, epigenomic discoveries can point to new drug targets, diagnostics, or ways to predict who will benefit from a therapy, affecting a biotech’s potential revenue, development risk and market value.
transcriptomics medical
"changes in epigenomics, changes in transcriptomics and changes in aneuploidy"
Analysis of all the RNA molecules a cell produces, showing which genes are actively being used at a given time—like reading which recipes are being pulled from a cookbook to see what’s actually being cooked. For investors, transcriptomics helps reveal how diseases work, whether a drug is hitting its target, and which patient groups are most likely to benefit, making it a tool for valuing therapies, guiding clinical trials, and spotting diagnostic or therapeutic opportunities.
aneuploidy medical
"changes in transcriptomics and changes in aneuploidy," said David Spetzler"
Aneuploidy is a condition in which cells have an abnormal number of chromosomes—too many or too few—like a deck of cards missing or repeating certain cards. It matters to investors because it underlies many cancers and genetic disorders, affects how diseases progress, and can determine whether diagnostic tests or drugs work; treatments targeting aneuploidy or tests that detect it can drive clinical value and commercial opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Demonstrates Superior Sensitivity and Specificity of Caris Detect

Results demonstrate the superiority of Whole Genome Sequencing compared 
to methylation-based approaches

IRVING, Texas, Feb. 26, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced an interim readout of Achieve 1, the Company's study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test. This interim readout of Achieve 1 represents a major milestone in Caris' goal to detect cancer earlier, when it is most treatable, through Whole Genome Sequencing, advanced AI and molecular insights.

Caris Detect leverages Caris' industry-leading molecular profiling data, which has surpassed one million cases processed and produced more than 50 billion molecular markers. This deep molecular foundation enables Caris' AI models to identify subtle biological signals associated with early-stage cancers with unprecedented resolution. 

Achieve 1 is evaluating Caris Detect across a broad population of patients, assessing its ability to detect multiple cancer types at early stages using a blood draw. For the undiagnosed cohort, which consisted of 1,505 samples, we utilized blood draws from subjects who had screening or symptomatic screening, a population reflecting a higher likelihood of cancer than the general population. We followed 22.5% of the subjects for approximately one year following their blood draw. Of these, 121 subjects had no symptoms of cancer, no significant risk factors of cancer and were not subsequently diagnosed with cancer, representing a healthy population.

The first phase of Achieve 1 utilized a cross-validation approach, with approximately 865 samples held out for a blinded validation that is in process. Caris expects to report those results later in the first quarter of 2026.

Study highlights and key performance data from the interim readout include:

  • Sensitivity:
    • 56.8% for Stage I (n=266)
    • 70.1% for Stage II (n=137)
    • 77.1% for Stage III (n=105)
    • 99.1% for Stage IV (n=109)
  • Sensitivity in Stage I and II Cancers (61.3% sensitivity)







Cancer

Stage I-II








Breast

53.0% (n=253)








Bowel

62.2% (n=45)








Prostate

78.9% (n=38)








Uterus

73.7% (n=19)








Lung

86.7% (n=15)








Pancreas

71.4% (n=7)








Head and Neck

100.0% (n=7)








Esophagus/Stomach

80.0% (n=5)








Cervix

80.0% (n=5)








Biliary Tract

100% (n=3)








Skin

50.0% (n=2)








Liver

100% (n=2)








Peritoneum

100% (n=1)








Bone

100% (n=1)

    • Specificity: 99.1% in the Asymptomatic Screening Population (n=121) and 95.3% in the Undiagnosed Population (n=1,505).
  • Sample Size: 2,122, across 1,505 undiagnosed and 617 cancers from stages I through IV.
  • 1,505 undiagnosed subjects from a screening and symptomatic screening population (the "Undiagnosed Population").
    • 121 of these subjects with follow-up data had no symptoms of cancer, no significant risk factors of cancer and were not subsequently diagnosed with cancer within one year following blood draw (the "Asymptomatic Screening Population").
    • In the ~600 undiagnosed subjects with one year of follow-up, roughly 7% of patients were subsequently diagnosed with cancer, indicating our enrollment criteria enriched for high-risk subjects.

"Our hypothesis has been that cancer is a disease driven by molecular aberrations that can manifest itself in many different forms. For example, driver mutations, changes in epigenomics, changes in transcriptomics and changes in aneuploidy," said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. "Most other attempts to derive insights into blood-based early detection modalities have relied upon epigenomics. Caris approached this from a broader biological perspective to encompass as many genomic alterations as can be attained from extreme ultra-deep Whole Genome Sequencing. This additional data has allowed us to achieve greater performance metrics than others and shows that methodologies focused on limited biological information are not sufficient to encompass the diversity of molecular aberrations driving cancer, especially in early-stage disease. Development of the next version of Caris Detect is currently underway with the aim of improving the already best-in-class performance with the incorporation of Whole Transcriptome Sequencing."

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: technical, operational and implementation requirements the failure of which affect the timing of or prevent commercialization of Caris Detect; future results regarding the blinded hold-out portion of the Achieve 1 samples as well as samples from Achieve 2; future performance and clinical utility of Caris Detect, including its AI models, when applied across larger real-world screening populations; developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on or about March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-completes-interim-readout-of-achieve-1-study-302699083.html

SOURCE Caris Life Sciences

FAQ

What sensitivity did Caris Detect report for Stage I cancers in Achieve 1 (CAI)?

Caris Detect showed 56.8% sensitivity for Stage I cancers in the interim readout. According to Caris, that figure is based on n=266 Stage I cases within the 2,122-sample dataset, reflecting early-stage detection performance.

How specific was Caris Detect in the asymptomatic screening group in Achieve 1 (CAI)?

The asymptomatic screening subgroup had 99.1% specificity in the interim readout. According to Caris, this metric came from 121 asymptomatic subjects followed for approximately one year after blood draw.

What overall Stage I–II detection performance did Achieve 1 report for Caris Detect (CAI)?

Achieve 1 reported 61.3% sensitivity for combined Stage I–II cancers in the interim analysis. According to Caris, this reflects aggregated performance across multiple cancer types in the 2,122-sample cohort.

How many samples and cohorts were included in the Achieve 1 interim readout for Caris Detect (CAI)?

The interim dataset included 2,122 samples, with 1,505 undiagnosed subjects and 617 cancer cases across stages I–IV. According to Caris, ~865 samples remain held out for a blinded validation.

When will Caris report the blinded validation results for Achieve 1 (CAI)?

Caris expects to report the blinded validation results later in Q1 2026. According to Caris, the first phase held out ~865 samples for a blinded validation currently in process.